Fig 1.
Patient inclusion flow chart.
Table 1.
Baseline demographics and clinical characteristics.
Table 2.
Primary and key secondary outcomes in the intention-to-treat population at week 52.
Fig 2.
SRI-4 response through 52 weeks in overall study population.
Proportion of patients reaching an SRI-4 response over the 52-week study period; SRI-4: Systemic Lupus Erythematosus Responder Index-4; *P ≤ 0.05; †P ≤ 0.01.
Fig 3.
Proportion of patients achieving an SRI-4 response who had glucocorticoid
≥ 10mg/day at baseline. I- SRI-4: Systemic Lupus Erythematosus Responder Index-4; *P ≤ 0.05; †P ≤ 0.01.
Fig 4.
Proportion of patients achieving an SRI-4 response who had SLEDAI-2K
≥ 10 at baseline. SLEDAI-2K: Systemic Lupus Erythematosus Disease Activity Index-2000; SRI-4: Systemic Lupus Erythematosus Responder Index-4; *P ≤ 0.05; †P ≤ 0.01.
Fig 5.
Improvement from baseline in SLEDAI-2K and BILAG organ systems through 52 weeks.
(A) Im(A) Improvement from baseline in the SLEDAI-2K organ system for the musculoskeletal domain. (B) Improvement from baseline in the SLEDAI-2K organ system for the mucocutaneous domain. (C) Improvement from baseline in the BILAG organ system for the musculoskeletal domain. (D) Improvement from baseline in the BILAG organ system for the mucocutaneous domain.
Table 3.
Overview of adverse events.